Review

The effects of transplanted cells in stem cell therapy for myocardial ischemia

Truc Le-Buu Pham* and Phuc Van Pham

Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University, Ho Chi Minh city, Viet Nam

Abstract

It is known that myocardial infarction (MI) causes damages to the heart tissue and that present medical therapies, such as medication, stenting and coronary artery bypass surgery, cannot recover the injured heart. Fortunately, advances in stem cell research have brought hope of full heart recovery for myocardial ischemia patients. There have been many studies using cell therapies for myocardial ischemia, from preclinical trials to clinical trials. However, the biggest concern is the effect of transplanted cells in myocardial recovery. This review will focus on analyzing both the positive and negative effects of transplanted cells in myocardial recovery to better understand the underlying biological mechanisms and ways to evaluate safety and efficacy of cell transplantation in myocardial ischemia treatment.

Keywords

Biological mechanism, effect, myocardial ischemia, stem cell therapy, transplanted cells

Introduction

Myocardial infarction (MI) kills cardiac cells and forms scars in the heart tissue. Although the formation of scars helps the injured heart cope with damages quickly, protects healthy tissue from further damage and prevents a cascade of adverse uncontrollable events (Azouz et al., 2004), the biochemical reactions during scar formation remain unclear. In fact, the physical and functional properties during heart tissue scarring is similar to those of normal tissues. Scarring has negative effects on the structure and activity of the infarcted heart (Cregg et al., 2014; Silver and Miller, 2004; Xu et al., 2004).
Current treatments such as lifestyle changes, medication, stent intervention or artery bypass surgery can only support the heart to slow the failure process, but cannot recover damaged heart tissues. The successful rate of all heart transplantation was very low. The number of novel postnatal heart tissue was low too and it was around 1% of total myocardium and decreased with age (Garbern and Lee, 2013).

Nowadays with the development of regenerative medicine, cell therapy can be expected to completely restore the structure and function of the damaged heart. Cell transplantations into ischemic areas have been investigated in small animal models (Avolio et al., 2015; Kim et al., 2015; Tang et al., 2015), large animal models (Kanazawa et al., 2015; Yee et al., 2014) and in clinical trials (Karantalis et al., 2012; Perin et al., 2015). Various cell types have been used in implantation, including mesenchymal stem cells (MSCs) (Kocher et al., 2001), induced pluripotent stem cells (iPSCs) (Cantz and Martin, 2010), cardiac progenitor cells (CPCs) (Garbern and Lee, 2013), cells derived from fetal tissue and adult cardiomyocytes (Soonpaa et al., 1994; Zhang et al., 2001), skeletal myoblasts (Menasche et al., 2001), muscle cells (Condorelli et al., 2001), embryonic-derived endothelial cells (ECs) (Condorelli et al., 2001), bone marrow-derived immature cells (Hattan et al., 2005), fibroblasts (Galli et al., 2005), smooth muscle cells (SMCs) (Harada et al., 2016) and bone marrow-c-kit positive and negative progenitor cells (Fazel et al., 2008; Fernandez-Aviles et al., 2004). In spite of the fact that results with the above have varied, they were largely similar in that there is a positive impact of cell transplantation on the recipients. It is important to understand how the transplanted cells act in heart wound healing and their efficacy. This review will focus on those issues.

**Effects of transplanted cells**

Most likely transplanted cells reduce negative remodeling by reducing the stiffness of the ventricular wall scar and restoring the lost heart muscle. Proposed mechanisms for this process include: (1) the transplanted cells secrete paracrine factors to protect the cells from apoptosis, mobilize the available cardiac stem cells, activate their proliferation and differentiation into heart cells, partake in neovascularization, reduce scar formation and limit inflammation; (2) the transplanted cells can fuse with host graft; (3) the transplanted cells can differentiate into cardiac muscle cells (Fig. 1).

**Secretion of growth factors**

Secretion of implanted cells plays an important role in repairing heart tissue damage. Adult stem cells, particularly MSCs, after transplantation can release a variety of cytokines, chemokines and growth factors involved in heart repair process (Deb et al., 2008; Li et al., 2012; Loffredo et al., 2011). These factors, in turn, induce neighboring stem cells to secrete cytokines and induce changes in the microenvironment which promote proliferation and differentiation of stem
cells (Behfar et al., 2002; Doyle et al., 2016; Gude et al., 2015; Kinnaird et al., 2004). In particular, properties such as myocardial protection and neovascularization of paracrine factors currently have been most widely studied. Moreover, the secreted factors also impact positively on the inflammation process, fibrogenic process, heart metabolism, heart contractions and/or endogenous cardiac regeneration. These effects may occur in different ways and are dependent on the microenvironment after infarction. These factors may also act in an autocrine fashion, impacting the cells which secrete them (Deb et al., 2008).

**Figure 1.** Effects and roles of transplanted cells in myocardial ischemia treatment. Transplanted cells can secrete useful factors to protect cells from apoptosis, mobilize resident stem cells, participate in the process of forming new vessels, reduce the size of the scar in the infarction area or limit the inflammation; these cells can also fuse with the host cells; or differentiate into heart cells. However, there are some things to consider when choosing the type of cells for transplantation such as their capable of tumorigenesis or arrhythmia causing.

**Protection of heart tissue**

The immediate impact of stem cells after grafting into the heart muscle is to release cytoprotective molecules to increase myocardial viability. These molecules inhibit apoptosis by activating AKT/PKB signaling pathway (Rosenberg et al., 2012; Yang et al., 2012). Some studies have shown that Akt-overexpressing MSCs and exosomes secreted from CXCR4-overexpressing or GATA4-overexpressing MSCs are able to significantly prevent apoptosis, thereby reducing infarction size (Kang et al., 2015; Noiseux et al., 2006; Yu et al., 2015). Other studies have shown that elements secreted from grafted bone marrow...
stem cells induce cardiomyocyte protection in the ischemic region (Broughton and Sussman, 2016; Dai et al., 2008; Xu et al., 2007). Cardiomyocytes differentiated from bone marrow monocytes (BM-MNCs) cultured under hypoxic conditions show they have inhibitory effects on apoptosis and can reduce infarction size when transplanted into the body (Kubal et al., 2006). When heart muscle cells and BM-MNCs obtained from the same patients were co-cultured, cell necrosis and apoptosis were significantly reduced; cell protection, however, did not occur when heart muscle cells with co-cultured with ECs or keratinocytes (Yoon et al., 2005).

Moreover, transplanted Akt-expressing MSCs also expressed secreted frizzled related protein 2 (Sfrp2), which increases cellular total -catenin of cardiomyocytes. The -catenin protected cardiomyocytes of newborn rats were stable against hypoxia and reoxygenation-induced apoptosis by blocking the pre-apoptotic effects of Wnt3a (Mirotou et al., 2007; Zhang et al., 2009). Akt-MSCs regulated the increase of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), and thymosin 4 (TB4). In turn, these factors promoted neovascularization, protection of myocardium and cardiac contractility (Gnecchi et al., 2006) (Fig. 2).

The overexpression of bFGF can enhance the recovery of contractile function and reduce infarction area after reperfusion. In fact, bFGF reduces the protein kinase C delta (PKC-d) displacements but does not affect PKC-alpha (PKC-a), PKC-epsilon (PKC-e), or PKC-zeta (PKC-z). PKC-d reduction protects heart cells and decreases the number of dead cells. In addition, bFGF has been shown to be related to the MAPK/ERK signaling pathway in heart cell protection, although the mechanism remains unclear (Baines et al., 2002; House et al., 2007; Padua et al., 1998; Rose et al., 2010; Srisakuldee et al., 2014). Akt activates a number of substrates, including members of the B-cell lymphoma 2 (Bcl-2) protein family, glycogen synthase kinase 3 beta (GSK-3) and endothelial nitric oxide synthase (eNOS). Nitric oxide (NO) synthesized from eNOS activates PKG through intracellular cGMP increasing. The substrates for protein kinase G (PKG) are thought to include SR regulation proteins and phospholamban, which promotes SR Ca\(^{2+}\) absorption thereby reducing the overload of cytosolic Ca\(^{2+}\). PKG is the final component of the signal transduction leading to activation of PKC-epsilon (PKC-e) mitochondrial pool. Activated PKC-e in turn activates mitochondrial ATP-dependent potassium channels (mK\(_{\text{ATP}}\)), promoting the reactive oxygen species (ROS) formation (Fig. 2).

The inhibition of mitochondrial permeability transition pore (MPTP) may occur as a result of PKC-e activation. Sarcolemmal K\(_{\text{ATP}}\) (sK\(_{\text{ATP}}\)) and mitochondrial connexin-43 (Cx43) are also considered components of the pre-regulation mechanism. The formation of ROS and reactive nitrogen species (RNS) are the results of mK\(_{\text{ATP}}\) opening and are mandatory components of the signaling cascade. It seems that ROS /RNS signaling is related to activation of kinases, such as p38, MAPK, PKC and JAK/STAT (Ferdinandy et al., 2007).
Figure 2. Transplanted cells protect heart tissue by increasing cell survival. CXCR4 or GATA4 overexpressing Mesenchymal Stem Cells released exosomes that prevented cells from apoptosis; the mechanism is unknown. Akt overexpressing MSCs increased bFGF leading to PKC-d reducing that increased PDH, Bcl2 and decreased Bad to protect cell survival. Akt overexpressing MSCs also secreted Sfrp2 which increased cellular total β-catenin of cardiomyocytes that blocked pre-apoptotic effects of Wnt3a and thereby protected cardiomyocytes. Akt activated eNOS and NO synthesized from eNOS activated PKG through intracellular cGMP increasing leading to activate PKC-e. PKC-e, in its turn, activate sKATP, mKATP, Cx43 and inhibit MPTP leading to cell protection.

The heart protects extracellular ligands, including adenosine, bradykinin and opioids, while activating multiple kinases, including p42/p44, MAPK/ERK, PI3K/Akt and PKC. The substrates of PKC related to the regulating protective mechanisms are still unknown. There is also evidence that the activation of PKG might occur as part of the post-regulating mechanism downstream of Akt/NO/cGMP, and may play a role in promoting the absorption of sarcoplasmic reticulum Ca^{2+}. It is known that activation of Akt inhibits GSK-3 and members of the chemokine (C-C motif) ligand 2 (Ccl-2) protein family, leading to inhibition of the formation of mK_{ATP}-mediated MPTP (Ferdinandy et al., 2007).

Normally, PKC exists in a non-activated state until it is stimulated by phospholipid diacyl glycerol (DAG)-derived second messengers. Intracellular ROS translocates to the subcellular target locations, including mitochondria, sarcolemmal membrane and gap junctions. Indeed, sK_{ATP}-mediated phosphorylation leads to shortening of the action potential, reducing the Ca^{2+}
overload during ischemia. Moreover, PKC-mediated phosphorylation of Cx43 reduces connexon permeability and prevents the expansion of damages between co-joined cells. PKC-mediated phosphorylation opens the mK\textsubscript{ATP}, conserves mitochondria function and forms local ROS. In turn, ROS may initiate PKC signaling via positive feedback. MPTP inhibition can occur by both direct mechanisms (e.g. via PKC phosphorylation) and indirect mechanisms (e.g. via mK\textsubscript{ATP} opening which reduces cell death after infarction). Receptor for activated c-kinase (RACK) treatment and erythropoietin also promote PKC activation, resulting in heart cell protection (Bearzi et al., 2007; Budas et al., 2007).

In summary, during ischemia reperfusion activated PKC-e in turn activates sK\textsubscript{ATP} and mK\textsubscript{ATP}, phosphorylates Cx43 and inhibits MPTP, leading to cell protection. However, activated PKC-d inhibits pyruvate dehydrogenase (PDH), decreases Bcl-2, increases Bcl-2-associated death promoter (Bad) protein, causing apoptosis and necrosis. Thus, transplanted cells protect myocardium by secreting various factors that activate PKC-e and inhibit PKC-d.

### Mobilization of resident stem cells

The discovery and recognition of the existence of cardiac stem cells led to a shift by researchers and physicians to explore the use of stem cells for new cardiovascular disease therapies (Bearzi et al., 2009; Hosoda et al., 2009; Urbanek et al., 2006). In the heart, cardiac stem cells (CSCs) have existed in their niches. Normally, these cells have kept “silent” in their niches, and have been nourished and controlled by feeding cells within the niches. Upon receiving trigger signals, CSCs undergo a symmetrical or asymmetrical proliferation; they separate from their niches and migrate to areas where they were needed to replace damaged or dying heart cells. However, the number of CSCs are very rare, at approximately 1 stem cell per 30,000 heart cells (Beltrami et al., 2003; Urbanek et al., 2006). Therefore, based on the normal growth rate of resident CSCs, when infarction occurs the number of cells needed to be replaced is much greater than the number of available cells, leading to a lack of intrinsic cardiac stem cells for replacement. This means that while the injured heart may be delayed in damages in the short term, heart failure cannot be reversed in the long term (Urbanek et al., 2003).

Studies have shown that when MSCs are grafted into the body in the absence of oxygen, they release HGF and IGF-1 to mobilize and activate resident CSCs (Gómez-Mauricio et al., 2016; Linke et al., 2005). Besides MSCs, endothelial progenitor cells (EPCs) play an important role. EPCs activate cardiac regenerative pools and promote the migration, proliferation and differentiation of CSCs (via secretion of cytokines such as VEGF, IGF-1 and SDF-1) (Urbich et al., 2005). These factors induce interstitial CSCs to move through the myocardium to necrotic myocardium and scar areas. There, they divide and differentiate into heart cells and become involved in the process of new blood vessel formation (Bian et al., 2014; Hosoda et al., 2009; Tillmanns et al., 2008). CSC invasion to
scar tissue is believed to be related to matrix metalloproteinase (MMP)-9 and -14 mediated regulation (Bax et al., 2012; Huang et al., 2011; Rota et al., 2008).

**Neovascularization**

MSC transplantation improves reperfusion efficiency by increasing the formation of new blood vessels. However, MSCs are rarely present in the new vessels; their main activity is to secrete angiogenic factors, such as VEGF, bFGF, angiopoietin-1, NO and HGF (Kinnaird et al., 2004; Zhao et al., 2010). These factors increase the permeability of the capillary wall, activate MMP, promote the proliferation and migration of ECs and vascular smooth muscle cells (VSMCs), and form new vessels in the lesions (Jiang et al., 2006; Louis and Zahradka, 2010; Nagaya et al., 2004). Besides MSCs, transplanted EPCs also enhance new vessel formation by releasing VEGF and stromal cell-derived factor 1 (SDF-1) into the cellular matrix, thereby promoting the migration and maturation of EPCs into ECs (Cochain et al., 2013; Urbich et al., 2005; Wu et al., 2006). Angiogenic cells have been implanted as hydrogel supplying scaffolds to increase microvasculature along infarction areas, thereby significantly improving coronary blood flow and ejection fraction after MI (Kim et al., 2012; Leblanc et al., 2013; Levit et al., 2013). In addition to angiogenesis factors, adult stem cells secrete TB4 and erythropoietin (EPO) (Lv et al., 2015; Smart et al., 2007). TB4 induces the proliferation and circuit network formation of epicardium-derived cells (EPDCs) and is involved in the intermediate PKC signaling pathway (Smart et al., 2013; Smart et al., 2007). Meanwhile, granulocyte colony stimulating factor (G-CSF) and EPO mobilize hematopoietic stem cells (HSCs) and EPCs from bone marrow for angiogenesis by activating Janus-activated tyrosine kinase 2 (JAK2) through STAT, PI3K/Akt and MAPK signaling pathways (Nagai and Komuro, 2012).

**Impact on extracellular matrix (ECM) and reduction of scar formation**

After infarction, scars are formed to replace injury tissues damaged by myocardial ischemia. During ischemia, the ECM secretion process is disordered due to heart cells dying and the body’s self-regulation. These impact the thickness of the developing scar, leading to an effect on the contraction of the surrounding heart tissue. A decrease in the ECM makes the ventricular wall thinner, causing left ventricular (LV) rupture while an increase in the ECM enhances fibrosis, leading to heart failure over time (Zamilpa and Lindsey, 2010).

From studies, it has been observed that grafted cells are capable of regulating scar formation through inhibition of fibroblast proliferation; furthermore, it has been shown that paracrine factor secretion alters ECM to improve cardiac functions (Berry et al., 2006). Transplanted MSCs reduce myofibroblasts through releasing MMPs (Almalki and Agrawal, 2016; Mias et al., 2009). In MI rat models, implanted MSCs reduce the expression of collagen types I and III, tissue inhibitor of metalloproteinase-1 (TIMP-1), MMP2, MMP9, and transforming growth factor-beta (TGF-beta) (Nagaya et al., 2005; Xu et al., 2005). It is
interesting that transplanted MSC cardiomyocyte (MSC-CM) also express the ability to reduce the scarring process by downregulating fibroblast proliferation and inhibiting the expression of collagen type I and type III in myofibroblasts (Ohnishi et al., 2007a; Ohnishi et al., 2007b). In addition, embryonic stem cell cardiomyocyte (ESC-CM) also show the ability to reduce scarring after MI (Leor et al., 2007). In sheep, MSCs injected one hour after MI also show changes in MMP-1, -2, -3, -7, -9, -13, membrane type 1-MMP (MT1-MMP), and TIMPs-1, -2, -4, at the border zone and infarct zone (Dixon et al., 2009).

Limiting inflammation

After MI, the inflammatory process is needed to mobilize immune cells to clear out dead heart cells and debris, and to stimulate ventricular remodeling (Frangogiannis, 2012; Frangogiannis et al., 2002). However, prolonged inflammatory responses would be detrimental to the remodeling process and ventricular function due to heart cell loss leading to negative impacts on ECM as well as formation of new vessels (Frangogiannis et al., 2002). Transplanted cells, such as MSCs or MSC-CMs, are able to limit the inflammatory process in the injured tissue. They weaken the proliferation of inflammatory CD68+ cells, decrease the expression of monocyte chemoattractant protein (MCP-1), increase the expression of genes involved in DNA repair, increase antioxidant enzymes and stimulate detoxifier systems, thereby improving cardiac function (Fuse et al., 2001; Ohnishi et al., 2007b; Ramalho-Santos et al., 2002).

Transplanted MSCs increase the number of M2 macrophages which were at the anti-inflammatory stage. The mechanism of this process is related to a variety of paracrine factors derived from transplanted MSCs, such as CCL2, galectin-1, interferon-γ, interleukin (IL)-1β, indoleamine-2,3-dioxygenase, IL-4, IL-6, IL-10, IL-13, prostaglandin E2 (PGE2), tumor necrosis factor (TNF)-α, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), NO, heme oxygenase-1, HGF, and TGF-beta (Ben-Mordechai et al., 2013; Bernardo and Fibbe, 2013; Du et al., 2008). Normally, the pro-inflammatory cytokines (e.g. NF-κB, IL-6 and TNF-) poison the heart muscle cells, causing detrimental effects on cardiac contractile function. Transplanted MSCs have been shown to inhibit activation of NF-κB, reduce production of TNF-α and IL-6, and increase the expression of anti-inflammatory cytokine IL-10, thereby limiting inflammation after infarction (Du et al., 2008; Onai et al., 2007). Moreover, the increase of indoleamine-pyrrole 2,3-dioxygenase (IDO) and PGE2 secretion also reduces T-cell activity and NK cell proliferation (Glennie et al., 2005; Nauta et al., 2006; Pradier et al., 2011; van den Akker et al., 2013).

Cell fusion

After infarction, grafted stem cells reduce cardiomyocyte apoptosis and stimulate cell proliferation via cell fusion (Alvarez-Dolado et al., 2003; Yang et al.,
Studies of bone marrow transplantation have proven that there is cell fusion between donor cells and recipient cells to form multi-nuclear cells (Alvarez-Dolado et al., 2003; Mayourian et al., 2016). Some studies have shown that stem cell transplantation can reprogram recipient cells, causing cardiomyocytes to re-enter the cell cycle; this contributes to regeneration of cardiac muscle and improvement of cardiac function (Yeh and Zhang, 2006).

Manuel Alvarez-Dolado et al. demonstrated that bone marrow stromal cells (BMSCs) derived from R26R mice (i.e. a Cre reporter mouse line) could fuse with Cre+ neurosphere cells after 4 days of co-culture. Moreover, BMSCs could fuse with Cre+ fibroblasts in primary culture. In vivo studies have revealed that bone marrow of actin-Cre-GFP mice could be grafted to irradiated R26R mice. The transplanted cells were shown to fuse with and exhibit similar morphology as local mature cardiomyocytes. The fused cells expressed GFP at 2 months after implantation; however, GFP expression was absent in most of the fused cells at 4 months after implantation, suggesting that interesting changes may occur inside the cells (Alvarez-Dolado et al., 2003). In accordance with Manuel et al., Yang et al. reported that transplanted bone marrow cells tend to integrate with local heart cells in infarcted regions rather than in healthy tissues. The infusion contributed to prevention of apoptosis of intergrated cardiomyocytes (Yang et al., 2012). In another interesting study, from Nygren et al., it was shown that transplanted HSC survive but do not transdifferentiate into cardiomyocytes within the infarcted myocardium, whereas X-gal and GFP positive cardiomyocytes or fused cardiomyocytes are seen outside the infarcted zone (Nygren et al., 2004).

**Differentiation of transplanted cells into heart cells**

Transplantation of stem cells or progenitor cells restore structure and function of heart tissue after infarction; this has been demonstrated both by preclinical studies and clinical trials. One of the proposed mechanisms is that transplanted cells and mobilized cells have the ability to differentiate into heart cells to replace damaged or necrotic cells (Kajstura et al., 2005; Nagata et al., 2016; Suzuki et al., 2015), possibly forming links with neighboring heart cells (Dimmeler et al., 2005).

So far, stem cell differentiation into heart muscle cells is proposed to be related to four major signaling pathways: canonical/non-canonical Wnt signaling pathway, bone morphogenetic protein (BMP) signaling pathway, fibroblast growth factor (FGF) signaling pathway, and Notch signaling pathway. Firstly, when the canonical Wnt pathway is inhibited through Wnt3A and b-catenin inhibition, this stimulates the differentiation of stem cells/precursor cells into cardiomyocytes (Pagliari et al., 2014). In addition, when non-canonical Wnt signaling pathway is activated through Wnt11 and Wnt5A activation, this also increases cell differentiation into cardiomyocytes (Pagliari et al., 2014). Secondly,
BMP-Smad1 inhibits Wnt/b-catenin and activates non-canonical Smad binding factors, leading to the transcription of activating transcription factor-2 (ATF2), while promoting major histocompatibility complex b (b-MHC) expression, contributing to heart cell differentiation (Parikh et al., 2015). Thirdly, FGF activates the PI3K/Akt signaling pathway to preserve stem cell properties (Parikh et al., 2015); moreover, via the MAPK/ERK signaling pathway they cause proliferation of cardiac progenitor cells but inhibition of their final differentiation into mature cardiomyocytes (Tirosh-Finkel et al., 2010). Repression of FGF signaling, therefore, accelerates the differentiation process of cardiac precursor cells (Tirosh-Finkel et al., 2010). Finally, Notch signaling plays a very important role in the regulation of stem cell differentiation into cardiomyocytes. It affects many kinds of cells- from transplanted cells, such as EPCs, MSCs and CPCs, to resident CSCs, immature cardiomyocytes and quiescent cardiomyocytes. Notch signaling is mediated by Jagged 1, NICD, Wnts, cyclin D1, RBP-Jk and Nkx2.5 (Gude et al., 2015; Luxan et al., 2016; Zhou and Liu, 2014).

Tumorigenesis of transplanted cells

Besides the positive effects of transplanted cells in experimental treatments for myocardial ischemia, there are negative impact, such as fertility tumorigenesis and cardiac arrhythmias.

Almost all adult stem cells and cardiac progenitor cells differentiated from stem cells have been shown to be safe; they did not produce tumors when transplanted into recipients (Ghodsizad et al., 2013; Huber et al., 2007). However, ESCs and iPSCs, have exhibited a high fertility tumorigenesis after transplantation (Ben-David and Benvenisty, 2011; Lee et al., 2013). Nussbaum et al. showed that after injection of undifferentiated-ESCs into rat models, tumor formation developed after transplantation (Nussbaum et al., 2007). In another study, Blin et al. grafted incompletely purified human ESC-derived cardiomyocytes into immune suppressed monkey models and found tumor formation in the transplanted monkeys (Blin et al., 2010). This suggests that unless the ESC-derived cardiomyocyte population is comprised of completely purified embryonic stem cells, it is very easy to form tumors from residual, unpurified ESCs (Tohyama et al., 2013). To date, there has been studies conducted to generate iPSCs without using viral vectors to circumvent the tumorigenesis of iPSCs (Okita et al., 2008).

Arrhythmia

Besides tumorigenesis, the potential of arrhythmia induction from transplanted cells has also received wide attention. In clinical trials, it was shown that transplant of myoblasts could led to arrhythmia occurrence (Leobon et al., 2003).
Additionally, a number of other studies also confirmed that transplanted beating heart cells could give rise to arrhythmia (Gillum and Sarvazyan, 2008; Menasche et al., 2008), while transplantation of human ESC (hESC)-derived cardiovascular progenitors into human fetal hearts showed harmony of the structure and function between transplanted cells and cardiac host cells (Ardehali et al., 2013). Moreover, the electromechanical coupling of hESC-derived cardiomyocytes and the suppression of cardiac arrhythmias in transplanted pig models seems to be related to the formation of electrical conduction bridges through scar tissues (Shiba et al., 2012). The problem of arrhythmia after transplantation has now become a major problem, attracting scientists and clinicians to investigate mechanisms to overcome it.

Conclusion

In conclusion, transplanted cells delivered by several different pathways have shown that they could recover the structure and function of the damaged heart. These mechanisms include secretion of factors that protect heart cells, neovascularization, prevention of the fibrosis process, limiting the inflammatory processes, and mobilizing resident stem cells to repair the heart (by fusing with host cells or differentiating into heart cells for cell loss replacement). However, in addition to positive effects, transplanted cells can also have undesirable roles, such as induction of tumorigenesis or arrhythmia. The chosen cell type for transplantation needs to be considered carefully before clinical application.

Abbreviations

AKT/PKB: serine/threonine-specific protein kinase/ protein kinase B; ATF2: activating transcription factor-2; b-MHC: major histocompatibility complex b; Bad: Bcl-2-associated death promoter; Bcl-2: B-cell lymphoma 2; bFGF: basic fibroblast growth factor; BM-MNCs: bone marrow monocytes; BMP: bone morphogenetic protein; BMSCs: bone marrow stromal cells; Ccl-2: chemokine (C-C motif) ligand 2; cGMP: cyclic guanosine monophosphate; CPCs: cardiac progenitor cells; CPCs: cardiac progenitor cells; CSCs: cardiac stem cells; Cx43: mitochondrial connexin 43; CXCR4: C-X-C chemokine receptor type 4; DAG: phospholipid diacyl glycerol; ECM: extracellular matrix; Ecs: endothelial cells; eNOS: endothelial nitric oxide synthase; EPCs: endothelial progenitor cells; EPDCs: epicardium-derived cells; EPO: erythropoietin; ESC-CM: embryonic stem cell cardiomyocyte; FGF: fibroblast growth factor; G-CSF: granulocyte colony stimulating factor; GATA4: GATA Binding Protein 4; GFP: green fluorescent protein; GSK-3: Glycogen synthase kinase 3; GSK-3: glycogen synthase kinase 3 beta; hESC: human embryonic stem cell; HGF: hepatocyte growth factor; HSCs: hematopoietic stem cells; IDO: indoleamine pyrrole 2,3-dioxygenase; IGIF-1: insulin-like growth factor-1; IL: interleukin; iPSCs: induced pluripotent stem cells; JAK/STAT: Janus kinase/ signal transducers and activators of transcription; JAK2: Janus-activated tyrosine kinase 2; LV:
Author Contributions

Truc Le-Buu Pham wrote and participated in editing the review. Phuc Van Pham oriented, gave important idea and revised the manuscript of this review.
References

Almalki, S.G., and Agrawal, D.K. (2016). Effects of matrix metalloproteinases on the fate of mesenchymal stem cells. Stem cell research & therapy 7, 129.

Alvarez-Dolado, M., Pardal, R., García-Verdugo, J.M., Fike, J.R., Lee, H.O., Pfeffer, K., Lois, C., Morrison, S.J., and Alvarez-Buylla, A. (2003). Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425, 968-973.

Ardehali, R., Ali, S.R., Inlay, M.A., Abilez, O.J., Chen, M.Q., Blauwkamp, T.A., Yazawa, M., Gong, Y., Nusse, R., Drukker, M., et al. (2013). Prospective isolation of human embryonic stem cell-derived cardiovascular progenitors that integrate into human fetal heart tissue. Proc Natl Acad Sci U S A 110, 3405-3410.

Avolio, E., Meloni, M., Spencer, H.L., Riu, F., Katare, R., Mangialardi, G., Oikawa, A., Rodriguez-Arabaolaza, I., Dang, Z., Mitchell, K., et al. (2015). Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair. Circ Res 116, e81-94.

Azouz, A., Razzaque, M.S., El-Hallak, M., and Taguchi, T. (2004). Immunoinflammatory responses and fibrogenesis. Med Electron Microsc 37, 141-148.

Baines, C.P., Zhang, J., Wang, G.W., Zheng, Y.T., Xiu, J.X., Cardwell, E.M., Bolli, R., and Ping, P. (2002). Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ Res 90, 390-397.

Bax, N.A., van Marion, M.H., Shah, B., Goumans, M.-J., Bouten, C.V., and van der Schaft, D.W. (2012). Matrix production and remodeling capacity of cardiomyocyte progenitor cells during in vitro differentiation. Journal of molecular and cellular cardiology 53, 497-508.

Bearzi, C., Leri, A., Monaco, F.L., Rota, M., Gonzalez, A., Hosoda, T., Pepe, M., Qanud, K., Ojaimi, C., and Bardelli, S. (2009). Identification of a coronary vascular progenitor cell in the human heart. Proceedings of the National Academy of Sciences 106, 15885-15890.

Bearzi, C., Rota, M., Hosoda, T., Tillmanns, J., Nascimbene, A., De Angelis, A., Yasuzawa-Amano, S., Trofimova, I., Siggins, R.W., and LeCapitaine, N. (2007). Human cardiac stem cells. Proceedings of the National Academy of Sciences 104, 14068-14073.

Behfar, A., Zingman, L.V., Hodgson, D.M., Rauzier, J.M., Kane, G.C., Terzic, A., and Puceat, M. (2002). Stem cell differentiation requires a paracrine pathway in the heart. FASEB J 16, 1558-1566.

Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara, H., Rota, M., Musso, E., and Urbanek, K. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763-776.

Ben-David, U., and Benvenisty, N. (2011). The tumorigenicity of human embryonic and induced pluripotent stem cells. Nature reviews Cancer 11, 268-276.

Ben-Mordechai, T., Holbova, R., Landa-Rouben, N., Harel-Adar, T., Feinberg, M.S., Abd Elrahman, I., Blum, G., Epstein, F.H., Silman, Z., Cohen, S., et al. (2013). Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J Am Coll Cardiol 62, 1890-1901.
Bernardo, M.E., and Fibbe, W.E. (2013). Mesenchymal stromal cells: sensors and switchers of inflammation. *Cell Stem Cell* 13, 392-402.

Berry, M.F., Engler, A.J., Woo, Y.J., Pirolli, T.J., Bish, L.T., Jayasankar, V., Morine, K.J., Gardner, T.J., Discher, D.E., and Sweeney, H.L. (2006). Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. *Am J Physiol Heart Circ Physiol* 290, H2196-2203.

Bian, S., Zhang, L., Duan, L., Wang, X., Min, Y., and Yu, H. (2014). Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. *Journal of Molecular Medicine* 92, 387-397.

Blin, G., Nury, D., Stefanovic, S., Neri, T., Guillevic, O., Brinon, B., Bellamy, V., Rucker-Martín, C., Barbry, P., Bel, A., et al. (2010). A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. *The Journal of clinical investigation* 120, 1125-1139.

Broughton, K.M., and Sussman, M.A. (2016). Empowering Adult Stem Cells for Myocardial Regeneration V2.0: Success in Small Steps. *Circ Res* 118, 867-880.

Budas, G.R., Churchill, E.N., and Mochly-Rosen, D. (2007). Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. *Pharmacological research* 55, 523-536.

Cantz, T., and Martin, U. (2010). Induced pluripotent stem cells: characteristics and perspectives. *Adv Biochem Eng Biotechnol* 123, 107-126.

Cochain, C., Channon, K.M., and Silvestre, J. (2013). Angiogenesis in the Infarcted Myocardium. *Antioxidants & Redox Signaling* 18, 1100-1113.

Condorelli, G., Borello, U., De Angelis, L., Latronico, M., Sirabella, D., Coletta, M., Galli, R., Balconi, G., Follenzi, A., Frati, G., et al. (2001). Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regeneration. *Proc Natl Acad Sci U S A* 98, 10733-10738.

Cregg, J.M., DePaul, M.A., Filous, A.R., Lang, B.T., Tran, A., and Silver, J. (2014). Functional regeneration beyond the glial scar. *Exp Neurol* 253, 197-207.

Dai, Y., Ashraf, M., Zuo, S., Uemura, R., Dai, Y.S., Wang, Y., Haider, H., Li, T., and Xu, M. (2008). Mobilized bone marrow progenitor cells serve as donors of cytoprotective genes for cardiac repair. *Journal of molecular and cellular cardiology* 44, 607-617.

Deb, A., Davis, B.H., Guo, J., Ni, A., Huang, J., Zhang, Z., Mu, H., and Dzau, V.J. (2008). SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autoregulatory loop of Wnt3a. *Stem Cells* 26, 35-44.

Dimmelé, S., Zeiher, A.M., and Schneider, M.D. (2005). Unchain my heart: the scientific foundations of cardiac repair. *The Journal of clinical investigation* 115, 572-583.

Dixon, J.A., Gorman, R.C., Stroud, R.E., Bouges, S., Hirotsugu, H., Gorman, J.H., 3rd, Martens, T.P., Itsou, S., Schuster, M.D., Plappert, T., et al. (2009). Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. *Circulation* 120, S220-229.

Doyle, M.J., Maher, T.J., Li, Q., Garry, M.G., Sorrentino, B.P., and Martin, C.M. (2016). Abcg2-Labeled Cells Contribute to Different Cell Populations in the Embryonic and Adult Heart. *Stem Cells Dev* 25, 277-284.
Du, Y.Y., Zhou, S.H., Zhou, T., Su, H., Pan, H.W., Du, W.H., Liu, B., and Liu, Q.M. (2008). Immuno-inflammatory regulation effect of mesenchymal stem cell transplantation in a rat model of myocardial infarction. Cytotherapy 10, 469-478.

Fazel, S.S., Chen, L., Angoulvant, D., Li, S.H., Weisel, R.D., Keating, A., and Li, R.K. (2008). Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB J 22, 930-940.

Ferdinandy, P., Schulz, R., and Baxter, G.F. (2007). Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacological reviews 59, 418-458.

Fernandez-Aviles, F., San Roman, J.A., Garcia-Brade, J., Fernandez, M.E., Penarrubia, M.J., de la Fuente, L., Gomez-Bueno, M., Cantalapiedra, A., Fernandez, J., Gutierrez, O., et al. (2004). Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 95, 742-748.

Frangogiannis, N.G. (2012). Regulation of the inflammatory response in cardiac repair. Circ Res 110, 159-173.

Frangogiannis, N.G., Smith, C.W., and Entman, M.L. (2002). The inflammatory response in myocardial infarction. Cardiovasc Res 53, 31-47.

Fuse, K., Kodama, M., Hanawa, H., Okura, Y., Ito, M., Shiono, T., Maruyama, S., Hirono, S., Kato, K., Watanabe, K., et al. (2001). Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. Clinical and experimental immunology 124, 346-352.

Galli, D., Innocenzi, A., Staszewsky, L., Zanetta, L., Sampaolesi, M., Bai, A., Martinoli, E., Carlo, E., Balconi, G., Fiordaliso, F., et al. (2005). Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells. Arterioscler Thromb Vasc Biol 25, 692-697.

Garbern, J.C., and Lee, R.T. (2013). Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12, 689-698.

Ghodsizad, A., Ruhipparwar, A., Bordel, V., Mirsaidighazi, E., Klein, H.M., Koerner, M.M., Karck, M., and El-Banayosy, A. (2013). Clinical application of adult stem cells for therapy for cardiac disease. Cardiovascular therapeutics 31, 323-334.

Gillum, N., and Sarvazyan, N. (2008). Adhesion proteins, stem cells, and arrhythmogenesis. Cardiovascular toxicology 8, 1-13.

Glennie, S., Soeiro, I., Dyson, P.J., Lam, E.W., and Dazzi, F. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105, 2821-2827.

Gneccchi, M., He, H., Noiseux, N., Liang, O.D., Zhang, L., Morello, F., Mu, H., Melo, L.G., Pratt, R.E., Ingwall, J.S., et al. (2006). Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb j 20, 661-669.

Gómez-Mauricio, G., Moscoso, I., Martin-Cacho, M.-F., Crisóstomo, V., Prat-Vidal, C., Báez-Díaz, C., Sánchez-Margallo, F.M., and Bernad, A. (2016). Combined administration of mesenchymal stem cells overexpressing IGF-1 and HGF enhances neovascularization but moderately improves cardiac regeneration in a porcine model. Stem cell research & therapy 7, 94.
Gude, N., Joyo, E., Toko, H., Quijada, P., Villanueva, M., Hariharan, N., Sacchi, V., Truffa, S., Joyo, A., Voelkers, M., et al. (2015). Notch activation enhances lineage commitment and protective signaling in cardiac progenitor cells. Basic Res Cardiol 110, 29.

Harada, S., Nakamura, Y., Shiraya, S., Fujiwara, Y., Kishimoto, Y., Onohara, T., Otsuki, Y., Kishimoto, S., Yamamoto, Y., Hisatome, I., et al. (2016). Smooth muscle cell sheet transplantation preserve cardiac function and minimize cardiac remodeling in a rat myocardial infarction model. J Cardiothorac Surg 11, 131.

Hattan, N., Kawaguchi, H., Ando, K., Kuwabara, E., Fujita, J., Murata, M., Suematsu, M., Mori, H., and Fukuda, K. (2005). Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice. Cardiovasc Res 65, 334-344.

Hosoda, T., D'Amario, D., Cabral-Da-Silva, M.C., Zheng, H., Padin-Iruegas, M.E., Ogorek, B., Ferreira-Martins, J., Yasuzawa-Amano, S., Amano, K., and Ide-Iwata, N. (2009). Clonality of mouse and human cardiomyogenesis in vivo. Proceedings of the National Academy of Sciences 106, 17169-17174.

House, S.L., Melhorn, S.J., Newman, G., Doetschman, T., and Schultz Jel, J. (2007). The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol 293, H354-365.

Huang, W., Wang, T., Zhang, D., Zhao, T., Dai, B., Ashraf, A., Wang, X., Xu, M., Millard, R.W., and Fan, G.-C. (2011). Mesenchymal stem cells overexpressing CXCR4 attenuate remodeling of postmyocardial infarction by releasing matrix metalloproteinase-9. Stem cells and development 21, 778-789.

Huber, I., Itzhaki, I., Caspi, O., Arbel, G., Tzukerman, M., Gepstein, A., Habib, M., Yankelson, L., Kehat, I., and Gepstein, L. (2007). Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. Faseb j 21, 2551-2563.

Jiang, S., Haider, H., Idris, N.M., Salim, A., and Ashraf, M. (2006). Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 99, 776-784.

Kajstura, J., Rota, M., Whang, B., Cascapera, S., Hosoda, T., Bearzi, C., Nurzynska, D., Kasahara, H., Zias, E., Bonafe, M., et al. (2005). Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 96, 127-137.

Kanazawa, H., Tseliou, E., Malliaras, K., Yee, K., Dawkins, J.F., De Couto, G., Smith, R.R., Kreke, M., Seinfeld, J., Middleton, R.C., et al. (2015). Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circ Heart Fail 8, 322-332.

Kang, K., Ma, R., Cai, W., Huang, W., Paul, C., Liang, J., Wang, Y., Zhao, T., Kim, H.W., Xu, M., et al. (2015). Exosomes Secreted from CXCR4 Overexpressing Mesenchymal Stem Cells Promote Cardioprotection via Akt Signaling Pathway following Myocardial Infarction. Stem Cells Int 2015, 659890.

Karantalis, V., Balkan, W., Schulman, I.H., Hatzistergos, K.E., and Hare, J.M. (2012). Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol 303, H256-270.
Kim, D.H., Kshitiz, Smith, R.R., Kim, P., Ahn, E.H., Kim, H.N., Marban, E., Suh, K.Y., and Levchenko, A. (2012). Nanopatterned cardiac cell patches promote stem cell niche formation and myocardial regeneration. *Integrative biology : quantitative biosciences from nano to macro* 4, 1019-1033.

Kim, P.J., Mahmoudi, M., Ge, X., Matsuura, Y., Toma, I., Metzler, S., Kooreman, N.G., Ramunas, J., Holbrook, C., McConnell, M.V., et al. (2015). Direct evaluation of myocardial viability and stem cell engraftment demonstrates salvage of the injured myocardium. *Circ Res* 116, e40-50.

Kinnaird, T., Stabile, E., Burnett, M.S., Lee, C.W., Barr, S., Fuchs, S., and Epstein, S.E. (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res* 94, 678-685.

Kocher, A.A., Schuster, M.D., Szabolcs, M.J., Takuma, S., Burkhoff, D., Wang, J., Homma, S., Edwards, N.M., and Itescu, S. (2001). Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 7, 430-436.

Kubal, C., Sheth, K., Nadal-Ginard, B., and Galinanes, M. (2006). Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. *The Journal of thoracic and cardiovascular surgery* 132, 1112-1118.

Leblanc, A.J., Nguyen, Q.T., Tourroo, J.S., Aird, A.L., Chang, R.C., Ng, C.K., Hoyoing, J.B., and Williams, S.K. (2013). Adipose-derived cell construct stabilizes heart function and increases microvascular perfusion in an established infarct. *Stem cells translational medicine* 2, 896-905.

Lee, A.S., Tang, C., Rao, M.S., Weissman, I.L., and Wu, J.C. (2013). Tumorigenicity as a Clinical Hurdle for Pluripotent Stem Cell Therapies. *Nat Med* 19, 998-1004.

Leobon, B., Garicn, I., Menasche, P., Vilquin, J.T., Audinat, E., and Charpak, S. (2003). Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. *Proc Natl Acad Sci U S A* 100, 7808-7811.

Leor, J., Gerecht, S., Cohen, S., Miler, L., Holbova, R., Ziskind, A., Shachar, M., Feinberg, M.S., Guetta, E., and Itskovitz-Eldor, J. (2007). Human embryonic stem cell transplantation to repair the infarcted myocardium. *Heart (British Cardiac Society)* 93, 1278-1284.

Levit, R.D., Landazuri, N., Phelps, E.A., Brown, M.E., Garcia, A.J., Davis, M.E., Joseph, G., Long, R., Safley, S.A., Suever, J.D., et al. (2013). Cellular encapsulation enhances cardiac repair. *Journal of the American Heart Association* 2, e000367.

Li, T.S., Cheng, K., Malliaras, K., Smith, R.R., Zhang, Y., Sun, B., Matsushita, N., Blusztajn, A., Terrovitis, J., Kusuoka, H., et al. (2012). Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiospheres-derived cells. *J Am Coll Cardiol* 59, 942-953.

Linke, A., Müller, P., Nurzynska, D., Casarsa, C., Torrella, D., Nascimbene, A., Castaldo, C., Cascafera, S., Böhm, M., and Quaini, F. (2005). Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. *Proceedings of the National Academy of Sciences of the United States of America* 102, 8966-8971.

Loffredo, F.S., Steinhauser, M.L., Gannon, J., and Lee, R.T. (2011). Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. *Cell Stem Cell* 8, 389-398.
Louis, S.F., and Zahradka, P. (2010). Vascular smooth muscle cell motility: From migration to invasion. *Experimental & Clinical Cardiology* 15, e75-85.

Luxan, G., D’Amato, G., MacGrogan, D., and de la Pompa, J.L. (2016). Endocardial Notch Signaling in Cardiac Development and Disease. *Circ Res* 118, e1-e18.

Lv, W., Li, W., Xu, X., Jiang, H., and Bang, O.Y. (2015). Bone marrow mesenchymal stem cells transplantation promotes the release of endogenous erythropoietin after ischemic stroke. *Neural Regeneration Research* 10, 1265-1270.

Mayourian, J., Savizky, R.M., Sobie, E.A., and Costa, K.D. (2016). Modeling Electrophysiological Coupling and Fusion between Human Mesenchymal Stem Cells and Cardiomyocytes. *PLoS computational biology* 12, e1005014.

Menasche, P., Alfieri, O., Janssens, S., McKenna, W., Reichenspurner, H., Trinquet, L., Vilquin, J.T., Marolleau, J.P., Seymour, B., Larghero, J., et al. (2008). The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. *Circulation* 117, 1189-1200.

Menasche, P., Hagege, A.A., Scorsin, M., Pouzet, B., Desnos, M., Duboc, D., Schwartz, K., Vilquin, J.T., and Marolleau, J.P. (2001). Myoblast transplantation for heart failure. *Lancet* 357, 279-280.

Mias, C., Lairez, O., Trouche, E., Roncalli, J., Calise, D., Seguelas, M.H., Ordener, C., Pierrecchi-Marti, M.D., Auge, N., Salvayre, A.N., et al. (2009). Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. *Stem Cells* 27, 2734-2743.

Mirotouso, M., Zhang, Z., Deb, A., Zhang, L., Gncachi, M., Noiseux, N., Mu, H., Pachori, A., and Dzau, V. (2007). Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. *Proc Natl Acad Sci U S A* 104, 1643-1648.

Nagai, T., and Komuro, I. (2012). Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function. *Am J Physiol Heart Circ Physiol* 303, H501-512.

Nagata, H., Li, M., Kohbayashi, E., Hoshiga, M., Hanafusa, T., and Asahi, M. (2016). Cardiac Adipose-Derived Stem Cells Exhibit High Differentiation Potential to Cardiovascular Cells in C57BL/6 Mice. *Stem cells translational medicine* 5, 141-151.

Nagaya, N., Fujii, T., Iwase, T., Ohgushi, H., Itoh, T., Uematsu, M., Yamagishi, M., Mori, H., Kangawa, K., and Kitamura, S. (2004). Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. *Am J Physiol Heart Circ Physiol* 287, H2670-2676.

Nagaya, N., Kangawa, K., Itoh, T., Iwase, T., Murakami, S., Miyahara, Y., Fujii, T., Uematsu, M., Ohgushi, H., Yamagishi, M., et al. (2005). Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. *Circulation* 112, 1128-1135.

Nauta, A.J., Kruisselbrink, A.B., Lurvink, E., Willemze, R., and Fibbe, W.E. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. *Journal of immunology (Baltimore, Md : 1950)* 177, 2080-2087.

Noiseux, N., Gncachi, M., Lopez-Ilasaca, M., Zhang, L., Solomon, S.D., Deb, A., Dzau, V.J., and Pratt, R.E. (2006). Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. *Mol Ther* 14, 840-850.
Nussbaum, J., Minami, E., Laflamme, M.A., Virag, J.A., Ware, C.B., Masino, A., Mushkeli, V., Pabon, L., Reinecke, H., and Murry, C.E. (2007). Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. Faseb j 21, 1345-1357.

Nygren, J.M., Jovinge, S., Breitbach, M., Sawen, P., Roll, W., Hescheler, J., Taneera, J., Fleischmann, B.K., and Jacobsen, S.E. (2004). Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10, 494-501.

Ohnishi, S., Yanagawa, B., Tanaka, K., Miyahara, Y., Obata, H., Kataoka, M., Kodama, M., Ishibashi-Ueda, H., Kangawa, K., Kitamura, S., et al. (2007a). Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. Journal of molecular and cellular cardiology 42, 88-97.

Ohnishi, S., Yasuda, T., Kitamura, S., and Nagaya, N. (2007b). Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells 25, 1166-1177.

Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science 322, 949-953.

Onai, Y., Suzuki, J., Maejima, Y., Haraguchi, G., Muto, S., Itai, A., and Isobe, M. (2007). Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 292, H530-538.

Padua, R.R., Merle, P.L., Doble, B.W., Yu, C.H., Zahradka, P., Pierce, G.N., Panagia, V., and Kardami, E. (1998). FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. Journal of molecular and cellular cardiology 30, 2695-2709.

Pagliari, S., Jelinek, J., Grassi, G., and Forte, G. (2014). Targeting pleiotropic signaling pathways to control adult cardiac stem cell fate and function. Frontiers in physiology 5, 219.

Parikh, A., Wu, J., Blanton, R.M., and Tzanakakis, E.S. (2015). Signaling Pathways and Gene Regulatory Networks in Cardiomyocyte Differentiation. Tissue engineering Part B, Reviews 21, 377-392.

Perin, E.C., Borow, K.M., Silva, G.V., DeMaria, A.N., Marroquin, O.C., Huang, P.P., Traverse, J.H., Krum, H., Skerrett, D., Zheng, Y., et al. (2015). A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. Circ Res 117, 576-584.

Pradier, A., Passweg, J., Villard, J., andKindler, V. (2011). Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity. Cell transplantation 20, 681-691.

Ramalho-Santos, M., Yoon, S., Matsuzaki, Y., Mulligan, R.C., and Melton, D.A. (2002). “Stemness”: transcriptional profiling of embryonic and adult stem cells. Science 298, 597-600.

Rose, B.A., Force, T., and Wang, Y. (2010). Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale. Physiological reviews 90.

Rota, M., Padin-IRuegas, M.E., Misao, Y., De Angelis, A., Maestroni, S., Ferreira-Martins, J., Fiumana, E., Rastaldo, R., Arcarese, M.L., and Mitchell, T.S. (2008). Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circulation research 103, 107-116.
Shiba, Y., Fernandes, S., Zhu, W.Z., Filice, D., Muskheli, V., Kim, J., Palpant, N.J., Gantz, J., Moyes, K.W., Reinecke, H., et al. (2012). Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489, 322-325.

Silver, J., and Miller, J.H. (2004). Regeneration beyond the glial scar. Nat Rev Neurosci 5, 146-156.

Smart, N., Dube, K.N., and Riley, P.R. (2013). Epicardial progenitor cells in cardiac regeneration and neovascularisation. Vascular pharmacology 58, 164-173.

Smart, N., Risebro, C.A., Melville, A.A., Moses, K., Schwartz, R.J., Chien, K.R., and Riley, P.R. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445, 177-182.

Soonpaa, M.H., Koh, G.Y., Klug, M.G., and Field, L.J. (1994). Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 264, 98-101.

Srisakuldee, W., Makazan, Z., Nickel, B.E., Zhang, F., Thliveris, J.A., Pasumarthi, K.B., and Kardami, E. (2014). The FGF-2-triggered protection of cardiac subsarcolemmal mitochondria from calcium overload is mitochondrial connexin 43-dependent. Cardiovasc Res 103, 72-80.

Suzuki, E., Fujita, D., Takahashi, M., Oba, S., and Nishimatsu, H. (2015). Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease. World journal of cardiology 7, 454-465.

Tang, X.L., Rokosh, G., Sanganalmath, S.K., Tokita, Y., Keith, M.C., Shirk, G., Stowers, H., Hunt, G.N., Wu, W., Dawn, B., et al. (2015). Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction. Circ Heart Fail 8, 757-765.

Tillmanns, J., Rota, M., Hosoda, T., Misao, Y., Esposito, G., Gonzalez, A., Vitale, S., Parolin, C., Yasuzawa-Amano, S., and Muraski, J. (2008). Formation of large coronary arteries by cardiac progenitor cells. Proceedings of the National Academy of Sciences 105, 1668-1673.

Tirosh-Finkel, L., Zeisel, A., Brodt-Ivenshitz, M., Shamai, A., Yao, Z., Seger, R., Domany, E., and Tzahor, E. (2010). BMP-mediated inhibition of FGF signaling promotes cardiomyocyte differentiation of anterior heart field progenitors. Development (Cambridge, England) 137, 2989-3000.

Tohyama, S., Hattori, F., Sano, M., Hishiki, T., Nagahata, Y., Matsuura, T., Hashimoto, H., Suzuki, T., Yamashita, H., Satoh, Y., et al. (2013). Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12, 127-137.

Urbanek, K., Cesselli, D., Rota, M., Nascimbene, A., De Angelis, A., Hosoda, T., Bearzi, C., Boni, A., Bolli, R., and Kajstura, J. (2006). Stem cell niches in the adult mouse heart. Proceedings of the National Academy of Sciences 103, 9226-9231.

Urbanek, K., Quaini, F., Tasca, G., Torella, D., Castaldo, C., Nadal-Ginard, B., Leri, A., Kajstura, J., Quaini, E., and Anversa, P. (2003). Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proceedings of the National Academy of Sciences 100, 10440-10445.

Urbich, C., Aicher, A., Heeschen, C., Dernbach, E., Hofmann, W.K., Zeiher, A.M., and Dimmeler, S. (2005). Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. Journal of molecular and cellular cardiology 39, 733-742.
van den Akker, F., de Jager, S.C., and Sluijter, J.P. (2013). Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. *Mediators of inflammation* 2013, 181020.

Wu, Y., Ip, J.E., Huang, J., Zhang, L., Matsushita, K., Liew, C.C., Pratt, R.E., and Dzau, V.J. (2006). Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. *Circ Res* 99, 315-322.

Xu, M., Uemura, R., Dai, Y., Wang, Y., Pasha, Z., and Ashraf, M. (2007). In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. *Journal of molecular and cellular cardiology* 42, 441-448.

Xu, X., Xu, Z., Xu, Y., and Cui, G. (2005). Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. *Coronary artery disease* 16, 245-255.

Xu, Y.J., Chapman, D., Dixon, I.M., Sethi, R., Guo, X., and Dhall, N.S. (2004). Differential gene expression in infarct scar and viable myocardium from rat heart following coronary ligation. *J Cell Mol Med* 8, 85-92.

Yang, W.J., Li, S.H., Weisel, R.D., Liu, S.M., and Li, R.K. (2012). Cell fusion contributes to the rescue of apoptotic cardiomyocytes by bone marrow cells. *J Cell Mol Med* 16, 3085-3095.

Yee, K., Malliaras, K., Kanazawa, H., Tseliou, E., Cheng, K., Luthringer, D.J., Ho, C.S., Takayama, K., Minamino, N., Dawkins, J.F., et al. (2014). Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. *PLoS One* 9, e113805.

Yeh, E.T., and Zhang, S. (2006). A novel approach to studying transformation of human stem cells into cardiac cells in vivo. *The Canadian journal of cardiology* 22 Suppl B, 66b-71b.

Yoon, Y.S., Wecker, A., Heyd, L., Park, J.S., Tkebuchava, T., Kusano, K., Hanley, A., Scadova, H., Qin, G., Cha, D.H., et al. (2005). Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. *The Journal of clinical investigation* 115, 326-338.

Yu, B., Kim, H.W., Gong, M., Wang, J., Millard, R.W., Wang, Y., Ashraf, M., and Xu, M. (2015). Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. *Int J Cardiol* 182, 349-360.

Zamilpa, R., and Lindsey, M.L. (2010). Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. *Journal of molecular and cellular cardiology* 48, 558-563.

Zhang, M., Methot, D., Poppa, V., Fujio, Y., Walsh, K., and Murry, C.E. (2001). Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. *Journal of molecular and cellular cardiology* 33, 907-921.

Zhang, Z., Deb, A., Zhang, Z., Pachori, A., He, W., Guo, J., Pratt, R., and Dzau, V.J. (2009). Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. *Journal of molecular and cellular cardiology* 46, 370-377.

Zhao, T., Zhao, W., Chen, Y., Ahokas, R.A., and Sun, Y. (2010). Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. *Microvascular research* 80, 188-194.
Zhou, X.L., and Liu, J.C. (2014). Role of Notch signaling in the mammalian heart. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al] 47, 1-10.